



## EyePoint Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 3, 2021

October 27, 2021

WATERTOWN, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 3, 2021 to report its third quarter 2021 financial results and discuss recent business highlights.

To access the live conference call, please dial (877) 312-7507 (domestic) or (631) 813-4828 (international) and reference conference ID 9396615. A live audio webcast of the event can be accessed via the Investors section of the Company website at [www.eyepointpharma.com](http://www.eyepointpharma.com). A webcast replay will also be available on the corporate website at the conclusion of the call.

### About EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert<sup>®</sup> technology for sustained intraocular drug delivery including EYP-1901, a potential twice-yearly intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ<sup>®</sup>, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU<sup>®</sup>, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. To learn more about the Company, please visit [www.eyepointpharma.com](http://www.eyepointpharma.com) and connect on Twitter and LinkedIn.

### Investors:

Christina Tartaglia  
Stern IR  
Direct: (212)-698-8700  
[christina.tartaglia@sternir.com](mailto:christina.tartaglia@sternir.com)

### Media Contact

Amy Phillips  
Green Room Communications  
Direct: 412-327-9499  
[aphillips@greenroompr.com](mailto:aphillips@greenroompr.com)



Source: EyePoint Pharmaceuticals, Inc.